Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Lipoxin A4 is an allosteric endocannabinoid that strengthens anandamide-induced CB1 receptor activation.

Literature DB >> 23204441

Lipoxin A4 is an allosteric endocannabinoid that strengthens anandamide-induced CB1 receptor activation.

Roger G Pertwee¹.

Abstract

Entities: Chemical Gene

Mesh：

Substances：

Year: 2012 PMID： 23204441 PMCID： PMC3529042 DOI： 10.1073/pnas.1218529110

Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN： 0027-8424 Impact factor: 11.205

× No keyword cloud information.

13 in total

Review 1. G protein-coupled receptor allosterism and complexing.

Authors: Arthur Christopoulos; Terry Kenakin
Journal: Pharmacol Rev Date: 2002-06 Impact factor: 25.468

Review 2. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.

Authors: R G Pertwee; A C Howlett; M E Abood; S P H Alexander; V Di Marzo; M R Elphick; P J Greasley; H S Hansen; G Kunos; K Mackie; R Mechoulam; R A Ross
Journal: Pharmacol Rev Date: 2010-12 Impact factor: 25.468

3. Allosteric modulation of the cannabinoid CB1 receptor.

Authors: Martin R Price; Gemma L Baillie; Adèle Thomas; Lesley A Stevenson; Morag Easson; Richard Goodwin; Adèle McLean; Lorraine McIntosh; Gillian Goodwin; Glenn Walker; Paul Westwood; Julia Marrs; Fiona Thomson; Phillip Cowley; Arthur Christopoulos; Roger G Pertwee; Ruth A Ross
Journal: Mol Pharmacol Date: 2005-08-19 Impact factor: 4.436

Review 4. The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.

Authors: Roger G Pertwee
Journal: AAPS J Date: 2005-10-24 Impact factor: 4.009

Review 5. Allosterism and cannabinoid CB(1) receptors: the shape of things to come.

Authors: Ruth A Ross
Journal: Trends Pharmacol Sci Date: 2007-11 Impact factor: 14.819

Review 6. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors.

Authors: A C Howlett; F Barth; T I Bonner; G Cabral; P Casellas; W A Devane; C C Felder; M Herkenham; K Mackie; B R Martin; R Mechoulam; R G Pertwee
Journal: Pharmacol Rev Date: 2002-06 Impact factor: 25.468

Review 7. International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family.

Authors: Richard D Ye; François Boulay; Ji Ming Wang; Claes Dahlgren; Craig Gerard; Marc Parmentier; Charles N Serhan; Philip M Murphy
Journal: Pharmacol Rev Date: 2009-06-04 Impact factor: 25.468

8. Isolation and structure of a brain constituent that binds to the cannabinoid receptor.

Authors: W A Devane; L Hanus; A Breuer; R G Pertwee; L A Stevenson; G Griffin; D Gibson; A Mandelbaum; A Etinger; R Mechoulam
Journal: Science Date: 1992-12-18 Impact factor: 47.728

9. PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats.

Authors: J G Horswill; U Bali; S Shaaban; J F Keily; P Jeevaratnam; A J Babbs; C Reynet; P Wong Kai In
Journal: Br J Pharmacol Date: 2007-06-25 Impact factor: 8.739

Review 10. Targeting the endocannabinoid system: to enhance or reduce?

Authors: Vincenzo Di Marzo
Journal: Nat Rev Drug Discov Date: 2008-05 Impact factor: 84.694

6 in total

Review 1. Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities.

Authors: Leepakshi Khurana; Ken Mackie; Daniele Piomelli; Debra A Kendall
Journal: Neuropharmacology Date: 2017-05-17 Impact factor: 5.250

2. Positive Allosteric Modulation of Cannabinoid Receptor Type 1 Suppresses Pathological Pain Without Producing Tolerance or Dependence.

Authors: Richard A Slivicki; Zhili Xu; Pushkar M Kulkarni; Roger G Pertwee; Ken Mackie; Ganesh A Thakur; Andrea G Hohmann
Journal: Biol Psychiatry Date: 2017-07-08 Impact factor: 13.382

Review 3. Selective modulation of the cannabinoid type 1 (CB₁) receptor as an emerging platform for the treatment of neuropathic pain.

Authors: Samuel D Banister; Kaavya Krishna Kumar; Vineet Kumar; Brian K Kobilka; Sanjay V Malhotra
Journal: Medchemcomm Date: 2019-03-18 Impact factor: 3.597

Lipoxin A4 is an allosteric endocannabinoid that strengthens anandamide-induced CB1 receptor activation.

Review 1. G protein-coupled receptor allosterism and complexing.

Review 2. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.

3. Allosteric modulation of the cannabinoid CB1 receptor.

Review 4. The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.

Review 5. Allosterism and cannabinoid CB(1) receptors: the shape of things to come.

Review 6. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors.

Review 7. International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family.

8. Isolation and structure of a brain constituent that binds to the cannabinoid receptor.

9. PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats.

Review 10. Targeting the endocannabinoid system: to enhance or reduce?

Review 1. Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities.

2. Positive Allosteric Modulation of Cannabinoid Receptor Type 1 Suppresses Pathological Pain Without Producing Tolerance or Dependence.

Review 3. Selective modulation of the cannabinoid type 1 (CB₁) receptor as an emerging platform for the treatment of neuropathic pain.

Review 4. Drug discovery strategies that focus on the endocannabinoid signaling system in psychiatric disease.

Review 5. Interactions of Cannabinoids With Biochemical Substrates.

Review 6. Potential role of lipoxin in the management of COVID-19: a narrative review.

Lipoxin A4 is an allosteric endocannabinoid that strengthens anandamide-induced CB1 receptor activation.

Review 1. G protein-coupled receptor allosterism and complexing.

Review 2. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.

3. Allosteric modulation of the cannabinoid CB1 receptor.

Review 4. The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.

Review 5. Allosterism and cannabinoid CB(1) receptors: the shape of things to come.

Review 6. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors.

Review 7. International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family.

8. Isolation and structure of a brain constituent that binds to the cannabinoid receptor.

9. PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats.

Review 10. Targeting the endocannabinoid system: to enhance or reduce?

Review 1. Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities.

2. Positive Allosteric Modulation of Cannabinoid Receptor Type 1 Suppresses Pathological Pain Without Producing Tolerance or Dependence.

Review 3. Selective modulation of the cannabinoid type 1 (CB1) receptor as an emerging platform for the treatment of neuropathic pain.

Review 4. Drug discovery strategies that focus on the endocannabinoid signaling system in psychiatric disease.

Review 5. Interactions of Cannabinoids With Biochemical Substrates.

Review 6. Potential role of lipoxin in the management of COVID-19: a narrative review.

Review 3. Selective modulation of the cannabinoid type 1 (CB₁) receptor as an emerging platform for the treatment of neuropathic pain.